Characterization of MDSCs and T cells in BM-transplanted chimeric mice. (A) Representative flow cytometric analysis of donor CD11b⁺GR-1⁺ cells from the BM, blood, spleens, and lungs of 3-month doxycycline-treated (+DOX) or untreated (−DOX) wild-type or bitransgenic BM-transplanted recipient mice. (B) Percentages of CD11b⁺GR-1⁺ cells from the BM, blood, spleens, and lungs of 3-month doxycycline-treated or untreated wild-type or bitransgenic BM-transplanted recipient mice were statistically analyzed. (C) Total numbers of CD11b⁺GR-1⁺ cells from the BM, spleens, and lungs of 3-month doxycycline-treated or untreated wild-type or bitransgenic BM-transplanted recipient mice were statistically analyzed. In all analyses, values were derived from 4 mice in each group (n = 4). *P < .05; **P < .01. (D) Representative flow cytometry analysis of CD4⁺ and CD8⁺ T cells from the BM, blood, spleens, and lungs from 3-month doxycycline-treated or untreated wild-type and bitransgenic BM-transplanted recipient mice. (E) Percentages of CD4⁺ and CD8⁺ T cells from the BM, blood, spleens, and lungs of 3-month doxycycline-treated or untreated wild-type or bitransgenic BM-transplanted recipient mice were statistically analyzed. (F) Total numbers of CD4⁺ and CD8⁺ T cells from the BM, spleens, and lungs from 3-month doxycycline-treated or untreated wild-type or bitransgenic BM-transplanted recipient mice were statistically analyzed. In all analyses, values were derived from 4 mice in each group (n = 4). *P < .05; **P < .01. (G) Death curve of doxycycline-treated or untreated wild-type or bitransgenic BM-transplanted recipient mice (n = 10). dnPPARγ>WT indicates bitransgenic to wild-type transplantation; WT>dnPPARγ, wild-type to bitransgenic transplantation.